Analyst Research
| Report Title | Price |
|---|---|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
H Lundbeck A/S Reorganizes European Operations
H Lundbeck A/S announced that the Company will organize its European markets into two regions, West and East, in order to manage the many new drug launches in the best possible way. Joao Rocha will take on responsibility for commercial activities in a majority of the Western European countries as regional vice president for Region West, while Michael Quiqueran-Beaujeu will lead Lundbeck’s activities in Eastern Europe as well as Turkey and Russia.
Latest Developments for H Lundbeck A/S
- H Lundbeck A/S and Takeda Pharmaceutical Company Limited's Vortioxetine Clinical Phase III Data Show Improvement in Symptoms of Major Depression
- H Lundbeck A/S Reaffirms FY 2013 Guidance
- H Lundbeck A/S Presents New Data on Selincro from Three Phase III Studies
- H Lundbeck A/S Announces Positive Results for Brintellix in Adult Patients with Major Depression and Inadequate Response to SSRI or SNRI Therapy
Latest Key Developments in Pharmaceuticals
- Herbalife Ltd Engages PricewaterhouseCoopers LLP As Auditors
- Baxter International Inc Receives Marketing Authorization For Hyqvia In European Union
- AMAG Pharmaceuticals Inc Announces Ferumoxytol Treatment Produced Hemoglobin Increases In Adult Iron Deficiency Anemia Patients With Gastrointestinal Disease
- Sanofi SA and Regeneron Pharmaceuticals Inc Announce Positive Phase 2a Results of Dupilumab in Asthma
- Share this
- Link this
- Digg this
Follow Reuters